Bayer appoints Nelson Ambrogio as president of U.S. pharmaceuticals

Bayer (BAYRY) announced a leadership change within its Pharmaceuticals’ Worldwide Markets organization. Effective May 1, Nelson Ambrogio, currently President of Bayer’s global Radiology business, will be appointed President of Bayer U.S. Pharmaceuticals. Ambrogio will guide the U.S. Pharmaceuticals organization into its next chapter of growth and build on the strong momentum and performance of the company’s pharmaceutical business in its largest and fastest-growing market. Ambrogio will be responsible for commercial pharmaceutical operations in the U.S. during a pivotal time of growth for the business, ensuring the continued strong performance of Bayer’s key growth brands in prostate cancer, cardiovascular care, women’s healthcare and as the company prepares its future portfolio in secondary stroke prevention. Ambrogio will join the company’s Worldwide Markets Leadership Team, reporting directly to Sebastian Guth, COO of Bayer’s Pharmaceuticals Division.